Ovarian Cancer

New Drug: Mirvetuximab Soravtansine in FRalpha Positive Ovarian Cancer

2023-01-10

  • Study

    Single-arm, Phase-3 trial (SONAYA)
    Platinum-resistant epithelial ovarian cancer (up to three prior lines of systemic therapy; all patients were required to have received bevacizumab)
    Mirvetuximab soravtansine at 6 mg/kg every 3 weeks (n=104)


  • Efficacy

    ORR: 31.7% [22.9 – 41.6]
    mDoR: 6.9 mos [5.6 – 9.7 mos]

  • Safety


    Adverse reactions 20%: vision impairment, keratopathy, peripheral neuropathy, ALT and AST increased



    • Article not yet published

    Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

    http://www.ncbi.nlm.nih.gov/pubmed/0

    Reviewed by Elvin Chalabiyev, MD on Jan 10, 2023